Melanoma vaccine trial signals transformative path for cancer care
TL;DR
The Washington Post profiles Mark Orwig and other melanoma patients in a Moderna/M Merck trial testing an mRNA-based cancer vaccine. Early results suggest the vaccine could prevent cancer recurrence after surgery, a finding experts say could transform cancer care and accelerate FDA approval, despite participants experiencing side effects and a tough recovery.
- What it was like to go through a trial that could revolutionize cancer treatment The Washington Post
- Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math WSJ
- Moderna, Merck breakthrough could usher in wave of cancer vaccines CNN
- A New mRNA Vaccine Could Prevent Skin Cancer From Returning The New York Times
- It now seems possible to vaccinate against cancer The Economist
Want the full story? Read the original reporting
Read on The Washington Post